UCB reports 7% increase in sales for 2014

Published: 3-Mar-2015
Finance

Three drugs now account for 50% of net sales


UCB reported a 7% increase in sales to €3.3bn in 2014.

The Belgian company saw continued growth with anti-inflammatory Cimzia, epilepsy drug Vimpat and the Neupro patch for Parkinson's and restless legs syndrome, which now account for 50% of net sales at €1.5bn.

Turnover for anti-epileptic drug Keppra fell 7% to €655m.

Chief Executive Jean-Christophe Tellier said the company was preparing to launch its next wave of potential new patient solutions: brivaracetam, epratuzumab and romosozumab and was excited about the progress in its early pipeline.

Other revenue in 2014 increased to €243m, mainly due to the payments from partners, Sanofi and the European Investment Bank (EIB).

Gross profit rose to €2.3bn (+6%), while recurring EBITDA was up 14% to €609m.

Looking forward, UCB expects the continued growth of Cimzia, Vimpat and Neupro to drive overall company growth. 2015 revenue should reach approximately €3.55–€3.65bn, while recurring EBITDA should increase to €710–€740m.

  • Companies:
  • UCB
See more

You may also like

Finance

Lannett to acquire Kremers Urban Pharmaceuticals for US$1.23bn

Read more
Lannett believes the acquisition will substantially increase and diversify its revenue base with profitable specialty products

Trending Articles

  1. Piramal Pharma Limited reports robust growth in CDMO and sustainability initiatives US$80 million Lexington expansion to double sterile fill-finish capacity
  2. GSK bolsters its US drug manufacturing capabilities with $800m investment The expansion will double the size and capacity of its Marietta site, supporting the manufacture of sterile liquid vaccines and production for clinical trials
  3. Lupin acquires Biocom in Russia Acquisition marks Lupin's foray into the Russian pharma market, which recorded RUB765bn in sales in 2014
  4. Axol Bioscience boosts its iPSC bioassay offering with Phenocell acquisition The acquisition will extend Axol's range of iPSC-derived cell lines, including skin and retinal cells — while also expanding its drug discovery services
  5. Eli Lilly to leverage ViaNautis Bio's nanovesicle technology for genetic medicine development ViaNautis' polyNaut nanovesicles can deliver genetic materials to specific tissues or cell types, allowing for more accurate therapeutic targeting

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Finance

Lannett to acquire Kremers Urban Pharmaceuticals for US$1.23bn

Lannett believes the acquisition will substantially increase and diversify its revenue base with profitable specialty products
Finance

Dr Reddy’s to buy allergies and respiratory franchises in India from UCB for €118m

Strengthens its presence in dermatology, respiratory and paediatrics medicines
Manufacturing

CPI-led UK biotech consortium secures £6.2m of government investment

Project aims to reduce the time it takes to bring biologics to market
Finance

Manufacturers to get more support from UK government

The UK government has announced the latest winners from a fund to help rebuild British manufacturing prowess
Finance

UCB pulls out of deal to sell Kremers Urban

Cites conflicting timing for the acquisition including its financing and the regulatory process
Finance

UCB to sell Kremers Urban to private equity for US$1.53bn

Belgian company will focus on its core business in neurology and immunology
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Fostering the development of innovative medicines

Confidence in the pharma sector seems to be picking up, with higher drug approvals in the US, M&A activity increasing and opportunities in emerging markets. However, healthcare reforms and pricing pressures are driving the industry to improve productivity and gain a better knowledge of disease mechanisms at the molecular level. Data sharing and collaborative projects seem to be the way forward
Subscribe now